welcome
Reuters

Reuters

Health

Health

Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand

Reuters
Summary
Nutrition label

81% Informative

Moderna has been struggling to shift away from its COVID vaccine to its newer RSV vaccine as its adoption has been slower than expected.

The vaccine maker aims to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million in 2026 .

The company is also betting on new products to help accelerate growth.

VR Score

92

Informative language

97

Neutral language

89

Article tone

semi-formal

Language

English

Language complexity

37

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links